B+
Bull case
20%
Probability
Target price
$2.88
Analysis reference price unavailable
Analysis 2025-11-17 · RankAlpha Sentiment AI
INBX
Inhibrx BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$1.92
Analysis reference price unavailable
Analysis 2025-11-17 · RankAlpha Sentiment AI
B-
Bear case
30%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2025-11-17 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-11-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Investor sentiment is cautious: trading reflects binary clinical risk and funding uncertainty, with limited conviction until clear readouts or confirmed partnership milestones [#10Qp12]. Some optimism exists around potential collaborations, but overall positioning remains defensive pending catalyst delivery [#PR-2025-09-12].
RankAlpha Sentiment AI - 2025-11-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventClinical readouts for lead programsHigh impact
Upcoming/ongoing trial readouts for lead candidates that can produce binary moves; positive efficacy or clean safety data should re-rate the stock, while negative signals would drive steep downside [#10Qp12].
2026-06-30catalystCash runway / financing updateHigh impact
Near‑term cash burn and financing needs are a key risk; announcements of dilution or weak funding options would compress valuation significantly.
2026-09-30catalystPartnership or licensing executionHigh impact
A strategic collaboration or favorable licensing terms would de‑risk development and extend runway; execution and milestone delivery determine magnitude of upside.
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-17 • Updated nightlySource: Internal modelMethodology